全科医生主导的简短叙事暴露干预对重症后创伤后应激症状的影响(PICTURE研究)
PICTURE多中心观察者盲随机对照试验在德国319家全科诊所纳入319名重症监护幸存后伴创伤后应激障碍症状的成人,比较全科医生主导的简短叙事暴露干预与基于德国指南的改良常规治疗。6个月时PDS-5组间差异4.7分(95%CI 1.6–7.8,P=0.003,d=0.37),12个月差异5.4分(95%CI 1.8–9.0,P=0.003,d=0.41),均低于预设最小临床重要差异6分;干预组抑郁、健康相关生活质量和残疾亦有更大改善。
要点
- 全科医生主导的简短叙事暴露干预在重症后PTSD症状上有统计学显著但低于最小临床重要差异的改善。
- 6个月PDS-5组间差异4.7分,12个月5.4分,效应量分别为0.37和0.41,效果持续到12个月。
- 干预组在抑郁、健康相关生活质量和残疾等次要结局上改善更明显,支持在基层进一步评估。
核心结论
- 在重症后伴PTSD症状的成人中,全科医生主导的简短叙事暴露干预可行,可减轻症状但降幅低于预设最小临床重要差异6分,且效果持续至12个月随访。
研究设计与样本
- 多中心、观察者盲、随机对照试验(PICTURE),在德国319家全科诊所开展,纳入319名18–85岁重症监护幸存伴PTSD症状的成人,随机分为干预组160例和改良常规治疗组159例。
主要发现
- 共筛查1283名重症监护出院患者,纳入319人,平均年龄57.7岁(SD 12.7),61%为男性,两组基线PDS-5均值均为30.6(SD 13.3)。
- 6个月时PDS-5组间平均差异4.7分(95%CI 1.6–7.8,P=0.003,Cohen's d=0.37),12个月时5.4分(95%CI 1.8–9.0,P=0.003,Cohen's d=0.41)。
- 271名(85%)完成6个月随访评估,247名(77%)完成12个月随访评估。
- 干预组在抑郁、健康相关生活质量和残疾等次要结局上改善更大。
关键数值与推荐
- 主要临床结局为6个月时自报PTSD症状,采用DSM-5创伤后诊断量表(PDS-5,范围0–80,分数越高症状越重),最小临床重要差异为6分。
- 干预组接受3次全科医生叙事暴露咨询和8次护士预定接触;对照组接受基于德国PTSD指南的改良常规治疗。
临床怎么用
- 该干预在初级保健中可行,可考虑用于重症后PTSD症状患者的基层管理,但症状改善幅度未达最小临床重要差异,需结合个体情况审慎使用。
- 干预效果持续至12个月,支持在基层对重症后PTSD症状开展进一步评估和随访。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effect of a novel brief general practitioner (GP)-led narrative exposure intervention on post-traumatic stress disorder (PTSD) symptoms after intensive care. DESIGN: Multicentre, observer blind, randomised controlled trial (PICTURE). SETTING: Primary care in 319 general practices across Germany. PARTICIPANTS: 319 adults (18-85 years) who have survived critical illness with symptoms of PTSD, discharged from intensive care and randomised to receive the intervention (n=160) or improved usual care (n=159) from a general practitioner. INTERVENTIONS: Intervention group participants had three narrative exposure consultations with a general practitioner and eight scheduled contacts with a nurse. Control group participants received improved treatment as usual based on the German PTSD guideline. MAIN OUTCOME MEASURES: The primary clinical outcome was self-reported PTSD symptoms using the Post-Traumatic Diagnostic Scale for DSM-5 (PDS-5, range 0-80, higher scores indicating more severe symptoms) at six months. The minimal clinically important difference was six points. Secondary outcomes included changes in depression, anxiety, patient activation, health related quality of life and disability at six and 12 months. RESULTS: Between 21 October 2018 and 18 January 2023, 1283 patients discharged from an intensive care unit were screened for PTSD symptoms. 319 study participants were randomly assigned either to the control group (n=159) or the intervention group (n=160). The mean patient age was 57.7 years (standard deviation (SD) 12.7), and 61% of participants were male. The mean baseline PDS-5 score was 30.6 (SD 13.3) in both groups. 271 (85%) study participants completed follow-up assessment after six months and 247 (77%) after 12 months. The intervention effect showed a mean between-group difference in the PDS-5 score of 4.7 points ((95% confidence interval 1.6 to 7.8); P=0.003, Cohen's d=0.37)) at six months and 5.4 points ((1.8 to 9.0); P=0.003, Cohen's d=0.41)) at 12 months. Among secondary outcomes, patients in the intervention group had greater improvements in depression, health related quality of life, and disability. CONCLUSIONS: In adults with symptoms of PTSD after critical illness, a brief narrative exposure intervention was feasible and showed a reduction of symptoms, which was less than the predefined minimal clinically important difference. The effect was found to be sustained at 12 months' follow-up. These findings support the further evaluation of this intervention in primary care. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03315390; DRKS-ID DRKS00012589.
引用
- Gensichen J, Schmidt KFR, Sanftenberg L, et al. Effects of a general practitioner-led brief narrative exposure intervention on symptoms of post-traumatic stress disorder after intensive care (PICTURE): multicentre, observer blind, randomised controlled trial. BMJ. 2025. PMID: 40335079. doi:10.1136/bmj-2024-082092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。